The Research Conferences organize the International Conference on Medical, Medicine, and Health Science (RICMMHS) scheduled for March 19th-20th, 2024. This conference serves as a focal point for leading academic scientists, researchers, and scholars to convene and share their insights and research findings across all facets of Medical, Medicine, and Health Sciences. RICMMHS offers a prime interdisciplinary platform fostering the exchange of ideas among researchers, practitioners, and educators. It aims to explore recent innovations, emerging trends, and address practical challenges in the dynamic fields of Medical, Medicine, and Health Sciences, contributing to the advancement and collaboration within these domains.

Read on researchconferences.in

The International Conference on Bioinformatics, Biomedicine, Biotechnology, and Computational Biology (EUIC3BCB) is scheduled for March 19th, 2024, in Louisville, United States. This recurring conference series facilitates an interactive platform for the presentation and discussion of advancements in Bioinformatics, Biomedicine, Biotechnology, and Computational Biology. Welcoming global participants, the event serves as a forum for establishing professional connections, exploring career opportunities, and fostering collaborations. Professionals from diverse sectors, including research, academia, industry, and government organizations, converge to exchange knowledge and gain insights into the latest technologies, techniques, and solutions in Biotechnology applied worldwide, contributing to the advancement of these fields.

Read on eurasiaweb.com

Engage in advancing personalized therapies for rare and common kidney diseases at the 6th CKD Drug Development Summit from March 19 to 21, 2024. Explore groundbreaking clinical strides like SGLT2s, GLP-1s, and ERAs for CKD. Delve into enhanced surrogate markers for outcomes, new targets, and pioneering research. This summit unites 200+ biopharma stakeholders across scientific, clinical, and outcomes realms for three days of focused discourse. The premier platform for industry leaders, regulators, and experts to propel kidney innovation toward the future of drug development.

Read on ckd3-summit.com

The 4th Wet AMD and Diabetic Eye Disease Drug Development Summit returns to Boston this March, gathering over 70 industry-based retinal vascular experts from renowned companies like Bayer, Boehringer Ingelheim, Genentech, Novartis, and OcuTerra. This dedicated forum aims to revolutionize the treatment of chronic, sight-threatening retinal vascular diseases, enhancing patient outcomes. The 2024 event features new contributors such as Aviceda Therapeutics, Adverum Biotechnologies, and others, presenting compelling content on novel targets, retinal imaging, clinical biomarkers, and innovative modalities for retinal and choroidal neovascularization. Scheduled from Tue, March 19, 2024, at 08:00 to Thu, March 21, 2024, at 15:00.

 [Read on wet-amd-drug-development.com](https://wet-amd-drug-development.com/)

The 4th TPD Summit Europe returns as the foremost gathering for Targeted Protein Degradation professionals in Europe and globally. Scheduled from Tue, 19 Mar 2024, at 08:00 to Thu, 21 Mar 2024, at 17:30, the summit explores novel degrader development, E3 ligase/ligand discovery, and overcoming safety concerns in PROTACs. With 35+ experts, it covers degrader drug development, from hit finding to clinical candidate assessment, fostering connections among 110+ professionals for revolutionary advancements benefiting patients worldwide.

 [Read on tpd-europe.com](https://tpd-europe.com/)

Join the pivotal 4th Operationalize Expanded Access Programs Summit in Boston from March 19th to March 21st, 2024, addressing the burgeoning interest in patient access to investigational medicines. This unique industry forum unites over 120 experts shaping Expanded Access Programs (EAPs), providing invaluable insights into global regulations, constructing reliable systems, and leveraging real-world data. Network with managed access teams from top pharmaceutical companies like Novartis, GSK, AstraZeneca, and more to explore innovative strategies, optimize EAP operationalization, and efficiently deliver life-saving treatments to patients. Don't miss this opportunity to join passionate EAP and clinical supply experts, physicians, and patients in revolutionizing access to vital therapies.

Read on operationalize-eap.com

The 3rd Cell Therapy Potency Assay Summit (Tue, 19 Mar 2024 - Thu, 21 Mar 2024) addresses the pressing challenge of developing robust potency assays within the dynamic cell therapy landscape. With recent clinical holds experienced by Mesoblast and Verve Therapeutics highlighting this need, over 120 analytical, quality control, and regulatory experts convene to collaboratively design more effective assays. This gathering aims to scientifically link mechanisms of action to potency assays, ensuring streamlined regulatory approval and reduced hold times. Industry insights from leading organizations like BMS, J and J, Atara Biotherapeutics, Fate Therapeutics, Health Canada, among others, offer valuable perspectives for developing reproducible assays, providing comprehensive understanding across different cell types and indications in autologous and allogeneic cell therapies.

Read on www.cell-therapy-potency-assay.com

Embark on an exploration at the 2nd Targeted Intracellular Delivery Summit, delving into pioneering drug delivery advancements. This year, discover beyond conventional limits, emphasizing cellular biology and intracellular mechanisms. Overcome endosomal barriers, extend therapies beyond the liver, and explore novel targets through case studies and a Pre-Conference Workshop Day. Engage in discussions and case studies led by industry giants like Sanofi, Merck and Co, Sana Biotechnology, and Capstan Therapeutics. This industry-led forum unites C-Level Executives, Researchers, and Directors, focusing on cellular mechanisms for precise intracellular drug delivery. Attend in March 2024 to witness the convergence of innovation and expertise for groundbreaking advancements in drug pipelines. 

[Read on targeted-intracellular-delivery](https://targeted-intracellular-delivery-summit.com/take-part/register/)

The rapidly evolving landscape from 2023 to 2024 has witnessed substantial industry strides. Advancements in artificial intelligence and robust biomarker development have revolutionized precision medicine, leading to numerous approvals, IND filings, and emerging companies. Reflecting these transformative changes, the Precision Medicine in Inflammatory Bowel Disease Summit returns from Tue, 19 Mar 2024 to Thu, 21 Mar 2024, uniting 100+ experts. This specialized gathering promises groundbreaking developments, accelerating drug optimization and ushering in a tailored approach to medicine, transcending the conventional one-size-fits-all paradigm.

Read on precision-medicine-in-ibd.com

In the ever-evolving landscape of European biopharma investment, the last year has seen significant milestones, with GSK investing €1 million in a biotech campus and AstraZeneca committing £1 billion to R&D and Corporate HQ. To thrive in this dynamic environment, the Lab Asset and Facility Management in Pharma Europe returns for its second year. This expert-led summit focuses on sharing insights to enhance operational excellence in laboratories across Europe. The event takes place from March 19 to 21, 2024, building on the success of 2023 and helping stakeholders navigate the challenges of the biopharma industry.

Read on lab-asset-facility-europe.com